Logon or register as member
New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction
The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment. These new recommendations provide a safe and effective treatment option to reduce mortality and morbidity and slow progression of the disease. To date, candesartan and valsartan are the only two ARBs with demonstrated safety and efficacy in this patient population.
Heart failure: The national burden
Download VBWG06_DataAlert_HF.ppt (10 slides - 0.2MB)
Related at vwbg.org
HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk
Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.
The CHARM program: Enhancement of RAAS manipulation in heart failure
Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).
MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function
Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women.
© 2017 - VBWG - University of Florida - All rights reserved